EU and US could reach trade deal this weekend - Reuters
Investing.com - JMP Securities has reiterated its Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a price target of $15.00. The stock has shown remarkable momentum, gaining nearly 97% over the past six months and about 17% in the past week alone, according to InvestingPro data.
The firm cited the larger AAV-naive Duchenne muscular dystrophy (DMD) patient population as a positive factor for the company’s outlook.
JMP views SGT-003’s capsid AAV-SLB-101 as differentiated, noting its better distribution and muscle tropism compared to alternatives in the market.
The research firm also highlighted the significantly lower proportion of empty capsids during production as a key advantage of Solid Biosciences’ technology.
JMP indicated it anticipates a significant update following the initial proof-of-concept data expected in late 2025.
In other recent news, Solid Biosciences has received FDA approval for its Investigational New Drug application for SGT-501, a gene therapy targeting catecholaminergic polymorphic ventricular tachycardia (CPVT). This approval marks a significant step for the company as it plans to begin a Phase 1b clinical trial to evaluate the therapy’s safety and efficacy. Additionally, Citi has initiated coverage on Solid Biosciences with a buy rating, highlighting the potential of its SGT-003 therapy in the Duchenne muscular dystrophy (DMD) market. The firm noted that SGT-003 has shown no evidence of liver toxicity, which may offer an advantage over competitors. Cantor Fitzgerald also reiterated an Overweight rating, expressing optimism about Solid Biosciences’ pipeline, including its new candidates for Friedreich’s ataxia and CPVT. The firm was encouraged by preliminary Phase 1/2 data from SGT-003, describing it as "highly encouraging." Furthermore, the recent investor meetings hosted by Cantor Fitzgerald underscored the company’s differentiation in the gene therapy landscape. Solid Biosciences’ management plans to discuss the regulatory pathway for SGT-003 with the FDA in the fourth quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.